Healthcare Industry News: Cambridge Heart
News Release - July 11, 2006
Microvolt T-Wave Alternans Testing To Be Covered by HumanaBEDFORD, Mass.--(HSMN NewsFeed)--July 11, 2006--Cambridge Heart, Inc. (OTCBB:CAMH ) today announced that Humana has issued a coverage policy on Microvolt T Wave Alternans testing, agreeing to cover the test for its beneficiaries. Humana's policy states:
"Humana members would be eligible under the Plan for MTWA testing using the spectral analytic method for the evaluation of risk of sudden cardiac death when the member meets the criteria for ICD placement."
Humana is one of the nations leading providers of healthcare benefits covering over 9 million people across the country.
"We are very pleased that Humana has joined the ranks of Medicare, Aetna and Cigna in agreeing to cover our Microvolt T-Wave Alternans Test" said David Chazanovitz, President and CEO of Cambridge Heart, Inc. "These four major national insurance companies are recognizing the value that MTWA can bring to the physician and the patient in helping at risk patients receive the most appropriate care. Consistent with Medicare and Aetna, Humana has specified our spectral analytic method as the only acceptable test methodology."
About Cambridge Heart
Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com
About the Cambridge Heart Microvolt T-Wave Alternans Test
The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.
Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
Source: Cambridge Heart
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.